The site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 1:30 - 4:30 pm (CEST).
If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
See More
The site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 1:30 - 4:30 pm (CEST).
If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
See MoreThe site is undergoing maintenance. Ordering can continue through fax and phone.
Sunday, August 16, 2026, 1:30 - 4:30 pm (CEST)
.If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Expression of human IL-8 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS (1.0 µg/ml final concentration) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554724). The PBMC were harvested, stained with 0.25 µg of FITC-mouse anti-human CD14 monoclonal antibody (FITC-M5E2, Cat. No. 555397), fixed, permeabilized, and subsequently stained with either 0.125 µg of PE-anti-human IL-8 (Cat. No. 554720; left panel), or 0.125 µg of PE-mouse IgG2b (Cat. No. 555058; middle panel), following BD PharMingen staining protocol. The data reflect gating on monocytes, based on forward and side scattered light signals. The quadrant markers for the bivariate dot plot were set based on autofluorescence controls (right panel).
Expression of human IL-8 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS (1.0 µg/ml final concentration) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554724). The PBMC were harvested, stained with 0.25 µg of FITC-mouse anti-human CD14 monoclonal antibody (FITC-M5E2, Cat. No. 555397), fixed, permeabilized, and subsequently stained with either 0.125 µg of PE-anti-human IL-8 (Cat. No. 554720; left panel), or 0.125 µg of PE-mouse IgG2b (Cat. No. 555058; middle panel), following BD PharMingen staining protocol. The data reflect gating on monocytes, based on forward and side scattered light signals. The quadrant markers for the bivariate dot plot were set based on autofluorescence controls (right panel).
Expression of human IL-8 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS (1.0 µg/ml final concentration) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554724). The PBMC were harvested, stained with 0.25 µg of FITC-mouse anti-human CD14 monoclonal antibody (FITC-M5E2, Cat. No. 555397), fixed, permeabilized, and subsequently stained with either 0.125 µg of PE-anti-human IL-8 (Cat. No. 554720; left panel), or 0.125 µg of PE-mouse IgG2b (Cat. No. 555058; middle panel), following BD PharMingen staining protocol. The data reflect gating on monocytes, based on forward and side scattered light signals. The quadrant markers for the bivariate dot plot were set based on autofluorescence controls (right panel).
Expression of human IL-8 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS (1.0 µg/ml final concentration) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554724). The PBMC were harvested, stained with 0.25 µg of FITC-mouse anti-human CD14 monoclonal antibody (FITC-M5E2, Cat. No. 555397), fixed, permeabilized, and subsequently stained with either 0.125 µg of PE-anti-human IL-8 (Cat. No. 554720; left panel), or 0.125 µg of PE-mouse IgG2b (Cat. No. 555058; middle panel), following BD PharMingen staining protocol. The data reflect gating on monocytes, based on forward and side scattered light signals. The quadrant markers for the bivariate dot plot were set based on autofluorescence controls (right panel).
Expression of human IL-8 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS (1.0 µg/ml final concentration) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554724). The PBMC were harvested, stained with 0.25 µg of FITC-mouse anti-human CD14 monoclonal antibody (FITC-M5E2, Cat. No. 555397), fixed, permeabilized, and subsequently stained with either 0.125 µg of PE-anti-human IL-8 (Cat. No. 554720; left panel), or 0.125 µg of PE-mouse IgG2b (Cat. No. 555058; middle panel), following BD PharMingen staining protocol. The data reflect gating on monocytes, based on forward and side scattered light signals. The quadrant markers for the bivariate dot plot were set based on autofluorescence controls (right panel).
Expression of human IL-8 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS (1.0 µg/ml final concentration) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554724). The PBMC were harvested, stained with 0.25 µg of FITC-mouse anti-human CD14 monoclonal antibody (FITC-M5E2, Cat. No. 555397), fixed, permeabilized, and subsequently stained with either 0.125 µg of PE-anti-human IL-8 (Cat. No. 554720; left panel), or 0.125 µg of PE-mouse IgG2b (Cat. No. 555058; middle panel), following BD PharMingen staining protocol. The data reflect gating on monocytes, based on forward and side scattered light signals. The quadrant markers for the bivariate dot plot were set based on autofluorescence controls (right panel).
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Immunofluorescent Staining and Flow Cytometric Analysis: The PE- and FITC-conjugated 27-35 immunoglobulin (Cat. No. 555057; 555058) are suitable mouse IgG2b isotype controls for assessing the level of background staining on paraformaldehyde fixed/saponin-permeabilized rat or human cells for flow cytometric analysis. Use at comparable concentrations to antibody of interest (e.g., ≤ 0.5 µg mAb/1 million cells) (see image, right panel). For specific methodology, please visit the protocols section or chapter on intracellular staining in the Immune Function Handbook, both of which are posted on our web site, www.bdbiosciences.com. The intracellular cytokine staining technique and use of blocking controls are described in detail by C. Prussin and D. Metcalfe.
This mouse IgG2b, κ isotype control is a monoclonal antibody, clone 27-35, that is specific for the dansyl (5-[dimethylamino] naphthalene-1-sulfonyl) hapten. The dansyl (DNS) hapten is not expressed on human cells or human cell lines. The 27-35 immunoglobulin was selected as an isotype control following testing that demonstrated low background staining on a variety of mouse and human tissues.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.